Vor Biopharma Inc.
VOR
$7.53
-$0.15-1.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 115.29% | -66.76% | -17.67% | -17.49% | -13.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.18% | 738.82% | 2.99% | 11.33% | -19.26% |
| Operating Income | -2.18% | -738.82% | -2.99% | -11.33% | 19.26% |
| Income Before Tax | -2,848.89% | -5,552.75% | -5.46% | -16.95% | 16.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2,848.89% | -5,552.75% | -5.46% | -16.95% | 16.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2,848.89% | -5,552.75% | -5.46% | -16.95% | 16.97% |
| EBIT | -2.18% | -738.82% | -2.99% | -11.33% | 19.26% |
| EBITDA | -5.32% | -757.46% | -3.45% | -11.80% | 19.64% |
| EPS Basic | -1,410.89% | -2,981.92% | 42.52% | -13.30% | 18.01% |
| Normalized Basic EPS | -1,412.82% | -2,921.77% | 42.52% | -13.30% | 18.01% |
| EPS Diluted | -1,410.89% | -2,981.92% | 42.52% | -13.30% | 18.01% |
| Normalized Diluted EPS | -1,412.82% | -2,921.77% | 42.52% | -13.30% | 18.01% |
| Average Basic Shares Outstanding | 95.17% | 83.41% | 83.48% | 3.22% | 1.27% |
| Average Diluted Shares Outstanding | 95.17% | 83.41% | 83.48% | 3.22% | 1.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |